[Microscopic polyangiitis as etiology for lung fibrosis--a known but often late-diagnosed cause]

Daniela Rosa Gompelmann1, Heinrich Wenz, Claus Peter Heussel

  • 1Pneumologie, Thoraxklinik Heidelberg, Heidelberg, Germany. daniela.gompelmann@thoraxklinik-heidelberg.de

Medizinische Klinik (Munich, Germany : 1983)
|June 18, 2009
PubMed
Abstract

Insights

Microscopic polyangiitis (MPA) can rarely present as lung fibrosis with exertional dyspnea. Early diagnosis and treatment of MPA are crucial for managing this rare but treatable cause of lung disease.

Area of Science:

  • Pulmonology
  • Rheumatology
  • Internal Medicine

Background:

  • Microscopic polyangiitis (MPA) is a rare autoimmune vasculitis.
  • Lung fibrosis as the initial symptomatic presentation of MPA is uncommon.
  • MPA is characterized by progressive exertional dyspnea, reticular shadowing on chest imaging, and elevated MPA-associated autoantibodies.

Observation:

  • A 78-year-old male presented with chronic exertional dyspnea.
  • Chest radiography revealed advanced lung fibrosis.
  • Laboratory tests detected MPA-associated autoantibodies, confirming the diagnosis.

Findings:

  • The patient was diagnosed with microscopic polyangiitis (MPA).
  • Treatment was initiated based on disease severity.
  • The presence of autoantibodies was key to diagnosis.

Implications:

  • Highlights MPA as a rare but treatable cause of lung fibrosis.
  • Emphasizes the importance of early diagnosis of MPA.
  • Underscores the need for prompt therapeutic intervention in suspected MPA cases, as the impact of pre-existing lung fibrosis on outcomes is uncertain.

Related Concept Videos

Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...